Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis
Authors' conclusion
GLP-1RAs are effective for body weight reduction and glycaemic improvement in individuals with T1D and overweight/obesity, with acceptable safety profiles. These findings provide evidence that GLP-1RAs can be effectively and safely used as adjunctive therapy to insulin in people with T1D, but additional robust randomised clinical trials are needed.
Study context
- Population
- Adults with T1D and BMI ≥25 kg/m² (overweight or obesity)13 studies
- Comparison
- GLP-1 RA adjunctive to insulin
- Outcome
- Changes in body weight, HbA1c and insulin dose
Methodological detailsrandom-effects models
- Random-effects models
Pooled result
As reported in the abstract
Body weight reduction
4.31 kg
95% CI 3.61–5.00 kg
HbA1c reduction
0.25%
95% CI 0.18–0.32%
Insulin dosage reduction, across all studies
9.24 U/day
95% CI 7.04–11.45 U/day
Further pooled results
Subgroup analysis by GLP-1 RA
- Semaglutide achieved the greatest reductions in all outcome measures
Safety
Hypoglycaemic episodes
- Increased; OR
- 1.34 (95% CI 1.02-1.76)
Hyperglycaemic episodes
- Decreased; OR
- 0.69 (95% CI 0.56-0.87)
Gastrointestinal and serious adverse events
- GI adverse events, incl. nausea and vomiting, significantly more frequent with GLP-1 RA
- No increase in serious adverse events
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →